Literature DB >> 25315017

Mesenchymal stromal cells engineered to produce IGF-I by recombinant adenovirus ameliorate liver fibrosis in mice.

Esteban J Fiore1, Juan M Bayo, Mariana G Garcia, Mariana Malvicini, Rodrigo Lloyd, Flavia Piccioni, Manglio Rizzo, Estanislao Peixoto, M Beatriz Sola, Catalina Atorrasagasti, Laura Alaniz, María A Camilletti, Mónica Enguita, Jesús Prieto, Jorge B Aquino, Guillermo Mazzolini.   

Abstract

Liver cirrhosis involves chronic wound healing and fibrotic processes. Mesenchymal stromal cells (MSCs) are multipotent adult progenitor cells that are used as vehicles of therapeutic genes. Insulin growth factor like-I (IGF-I) was shown to counteract liver fibrosis. We aimed at analyzing the effect of applying IGF-I overexpressing mouse bone marrow-derived MSCs on hepatic fibrosis. Fibrosis was induced by chronic thioacetamide application or bile duct ligation. MSCs engineered to produce green fluorescent protein (GFP) (AdGFP-MSCs) or IGF-I (AdIGF-I-MSCs) were applied systemically, and changes in collagen deposition and in the expression of key pro-fibrogenic and pro-regenerative genes/proteins were assessed. In addition, immunogenicity of transduced cells was analyzed. Liver fibrosis was further ameliorated after a single-dose application of AdIGF-I-MSCs when compared with AdGFP-MSCs and/or recombinant IGF-I treatments. Interestingly, an early and transitory upregulation in IGF-I and hepatocyte growth factor (HGF) mRNA expression was found in the liver of MSC-treated animals, which was more pronounced in AdIGF-I-MSCs condition. A reduction in hepatic stellate cell activation status was found after incubation with MSCs conditioned media. In addition, the AdIGF-I-MSCs cell-free supernatant induced the expression of IGF-I and HGF in primary cultured hepatocytes. From day 1 after transplantation, the proliferation marker proliferating cell nuclear antigen was upregulated in the liver of AdIGF-I-MSCs group, mainly in hepatocytes. MSCs were in vivo traced till day 14 after injection. In addition, multiple doses of Ad-IGF-I-MSCs likely suppressed antiviral immune response and it further reduced collagen deposition. Our results uncover early events that are likely involved in the anti-fibrogenic effect of genetically modified MSCs and overall would support the use of AdIGF-I-MSCs in treatment of liver fibrosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25315017      PMCID: PMC4356192          DOI: 10.1089/scd.2014.0174

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  24 in total

Review 1.  Mechanisms of hepatic fibrogenesis.

Authors:  Scott L Friedman
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

Review 2.  Mesenchymal stem cells as therapeutic tools and gene carriers in liver fibrosis and hepatocellular carcinoma.

Authors:  J B Aquino; M F Bolontrade; M G García; O L Podhajcer; G Mazzolini
Journal:  Gene Ther       Date:  2010-03-11       Impact factor: 5.250

Review 3.  Implications of the immunoregulatory functions of mesenchymal stem cells in the treatment of human liver diseases.

Authors:  Hu Lin; Ruonan Xu; Zheng Zhang; Liming Chen; Ming Shi; Fu-Sheng Wang
Journal:  Cell Mol Immunol       Date:  2010-11-22       Impact factor: 11.530

4.  No contribution of umbilical cord mesenchymal stromal cells to capillarization and venularization of hepatic sinusoids accompanied by hepatic differentiation in carbon tetrachloride-induced mouse liver fibrosis.

Authors:  Hongying Ren; Qinjun Zhao; Tao Cheng; Shihong Lu; Zhong Chen; Lei Meng; Xiaofan Zhu; Shaoguang Yang; Wen Xing; Yongdi Xiao; Qian Ren; Ying Chi; Dongsheng Gu; Renchi Yang; Zhong Chao Han
Journal:  Cytotherapy       Date:  2010-05       Impact factor: 5.414

5.  Mesenchymal stem cell infusion therapy in a carbon tetrachloride-induced liver fibrosis model affects matrix metalloproteinase expression.

Authors:  Vahideh Rabani; Mansoureh Shahsavani; Marzieh Gharavi; Abbas Piryaei; Zahra Azhdari; Hossein Baharvand
Journal:  Cell Biol Int       Date:  2010-04-27       Impact factor: 3.612

6.  Insulin-like growth factor I gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis leading to cirrhosis reversion in rats.

Authors:  Luciano Sobrevals; Carlos Rodriguez; José Lorenzo Romero-Trevejo; Gabor Gondi; Iñaki Monreal; Astrid Pañeda; Nerea Juanarena; Sara Arcelus; Nerea Razquin; Laura Guembe; Gloria González-Aseguinolaza; Jesús Prieto; Puri Fortes
Journal:  Hepatology       Date:  2010-03       Impact factor: 17.425

7.  Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function.

Authors:  James A Thomas; Caroline Pope; Davina Wojtacha; Andrew J Robson; Timothy T Gordon-Walker; Stephen Hartland; Prakash Ramachandran; Marielle Van Deemter; David A Hume; John P Iredale; Stuart J Forbes
Journal:  Hepatology       Date:  2011-06       Impact factor: 17.425

8.  Disruption of the growth hormone--signal transducer and activator of transcription 5--insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis.

Authors:  Leander Blaas; Jan-Wilhelm Kornfeld; Daniel Schramek; Monica Musteanu; Gernot Zollner; Judith Gumhold; Franziska van Zijl; Doris Schneller; Harald Esterbauer; Gerda Egger; Markus Mair; Lukas Kenner; Wolfgang Mikulits; Robert Eferl; Richard Moriggl; Josef Penninger; Michael Trauner; Emilio Casanova
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

9.  Activation of hepatic stellate cells is associated with cytokine expression in thioacetamide-induced hepatic fibrosis in mice.

Authors:  Rebeca Salguero Palacios; Martin Roderfeld; Stefanie Hemmann; Timo Rath; Srebrena Atanasova; Annette Tschuschner; Olav A Gressner; Ralf Weiskirchen; Jürgen Graf; Elke Roeb
Journal:  Lab Invest       Date:  2008-09-15       Impact factor: 5.662

10.  Hepatocyte growth factor suppresses profibrogenic signal transduction via nuclear export of Smad3 with galectin-7.

Authors:  Yutaka Inagaki; Kiyoshi Higashi; Miwa Kushida; Yun Yu Hong; Sachie Nakao; Reiichi Higashiyama; Tadashi Moro; Johbu Itoh; Toshiyuki Mikami; Toru Kimura; Goshi Shiota; Ichiro Kuwabara; Isao Okazaki
Journal:  Gastroenterology       Date:  2008-01-11       Impact factor: 22.682

View more
  32 in total

1.  Anti-TGFβ-1 receptor inhibitor mediates the efficacy of the human umbilical cord mesenchymal stem cells against liver fibrosis through TGFβ-1/Smad pathway.

Authors:  Ji Xuan; Wang Feng; Zheng-Tao An; Jian Yang; Hua-Bing Xu; Jing Li; Zhi-Fei Zhao; Wei Wen
Journal:  Mol Cell Biochem       Date:  2017-02-08       Impact factor: 3.396

Review 2.  Multipotent mesenchymal stromal cells: A promising strategy to manage alcoholic liver disease.

Authors:  Fernando Ezquer; Flavia Bruna; Sebastián Calligaris; Paulette Conget; Marcelo Ezquer
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

3.  Umbilical Cord Cell Therapy Improves Spatial Memory in Aging Rats.

Authors:  Marianne Lehmann; Maria F Zappa-Villar; Mariana G García; Guillermo Mazzolini; Martina Canatelli-Mallat; Gustavo R Morel; Paula C Reggiani; Rodolfo G Goya
Journal:  Stem Cell Rev Rep       Date:  2019-08       Impact factor: 5.739

4.  Blocking follistatin-like 1 attenuates liver fibrosis in mice by regulating transforming growth factor-beta signaling.

Authors:  Xiao-Hua Zhang; Yong Chen; Bin Li; Ji-Yong Liu; Chong-Mei Yang; Ming-Ze Ma
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

Review 5.  Current status and future prospects of mesenchymal stem cell therapy for liver fibrosis.

Authors:  Yang Guo; Bo Chen; Li-Jun Chen; Chun-Feng Zhang; Charlie Xiang
Journal:  J Zhejiang Univ Sci B       Date:  2016 Nov.       Impact factor: 3.066

Review 6.  Extracellular Vesicles and Hepatocellular Carcinoma: Opportunities and Challenges.

Authors:  Juan Wang; Xiaoya Wang; Xintong Zhang; Tingting Shao; Yanmei Luo; Wei Wang; Yunwei Han
Journal:  Front Oncol       Date:  2022-05-25       Impact factor: 5.738

Review 7.  Growth Hormone and Insulin-Like Growth Factor 1 Regulation of Nonalcoholic Fatty Liver Disease.

Authors:  Laura E Dichtel; Jose Cordoba-Chacon; Rhonda D Kineman
Journal:  J Clin Endocrinol Metab       Date:  2022-06-16       Impact factor: 6.134

8.  Identification of growth differentiation factor 15 as a pro-fibrotic factor in mouse liver fibrosis progression.

Authors:  Peng Qi; Ming-Ze Ma; Jing-Hua Kuai
Journal:  Int J Exp Pathol       Date:  2021-05-13       Impact factor: 2.793

Review 9.  Genetic modification by overexpression of target gene in mesenchymal stromal cell for treating liver diseases.

Authors:  Chenxia Hu; Lingfei Zhao; Lanjuan Li
Journal:  J Mol Med (Berl)       Date:  2021-01-02       Impact factor: 4.599

10.  Acceleration of TAA-Induced Liver Fibrosis by Stress Exposure Is Associated with Upregulation of Nerve Growth Factor and Glycopattern Deviations.

Authors:  Catalina Atorrasagasti; Flavia Piccioni; Sophia Borowski; Irene Tirado-González; Nancy Freitag; María José Cantero; Juan Bayo; Guillermo Mazzolini; Laura D Alaniz; Sandra M Blois; Mariana G Garcia
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.